神经退行症:2021年更新
1Neuropathology Brain Bank & Research CoRE, Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Free neuropathology
|June 7, 2023
概括
2020年神经病理学研究的主要亮点包括COVID-19的神经联系,阿尔茨海默病生物标志物的进展,以及对神经退行性疾病中陶氏蛋白和α-synuclein蛋白结构的洞察.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
背景情况:
- 2020年在理解神经退行性疾病方面取得了重大进展.
- 研究趋势从转录组学发展到蛋白质组学,专注于质贡献和蛋白质修饰.
- COVID-19与神经症状之间的新兴联系刺激了新的研究方向.
研究的目的:
- 审查2020年实验和诊断神经病理学的有影响力的研究主题和趋势.
- 为各种神经退行性疾病的关键发展提供平衡的概述.
- 突出阿尔茨海默病,亨廷顿病和慢性创伤性脑病变的变革性研究.
主要方法:
- 从2020年开始审查选定的手稿和研究趋势.
- 分析使用蛋白质组学,冷电子显微镜和敏感生物标志物分析的研究.
- 检查与蛋白质聚合,细胞应激反应和质细胞功能相关的分子数据.
主要成果:
- COVID-19引发神经退行变化的潜力是一个重要的新兴研究领域.
- 蛋白质组学揭示了在阿尔茨海默氏症和陶蛋白修饰中质的作用.
- 对于阿尔茨海默病的血生物标志物的进展使得在血液中检测到异常的.
- 低温电子显微镜提供了近原子分辨率的α-synuclein聚合物和tau包含.
- 研究揭示了在亨廷顿病中,α-synuclein菌株和细胞适应对内质网膜应激的细胞适应.
- 天体细胞在慢性创伤性脑病变中的作用得到了突出表现.
结论:
- 2020年的研究强调了神经退行性疾病的复杂性,在分子理解和诊断方面取得了重大进展.
- 病毒感染和神经退行之间的相互作用,特别是COVID-19,是未来研究的关键途径.
- 技术进步,如冷电子显微镜和敏感生物标志物测试,正在彻底改变神经病理学研究.
相关概念视频
01:15Parkinson's Disease: Overview
612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
01:26Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
01:22Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:15Neurogenesis and Regeneration of Nervous Tissue
886
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
886
01:01Neuroplasticity
604
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
604